Statins and Protein Prenylation in Cancer Cell Biology and Therapy

Author(s): Carmen Garcia-Ruiz, Albert Morales, Jose C. Fernandez-Checa

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 12 , Issue 4 , 2012

Become EABM
Become Reviewer
Call for Editor


The use of statins has scaled up to become one of the most prescribed medicines in the world and have been very useful in the manegement of cardiovascular diseases and related mortality. The disclosure of their chemical structure similar to that of hydroxy methyl glutaryl-CoA (HMG-CoA) revealed their ability to compete with and inhibit the rate-limiting enzyme HMG-CoA reductase that catalyzes the synthesis of mevalonate, which then serves as the precursor for isoprenoids and cholesterol in the mevalonate pathway. While most of the effects of statins are associated with the lowering of cellular cholesterol levels, it is clear that they also blunt the non-sterol branch of the mevalonate pathway, decreasing formation of isoprenoids and altering protein-prenylation, a critical event in the posttranslational modulation of proteins involved in the regulation of cell cycle progression, proliferation and signaling pathways. Randomized controlled trials for the prevention of cardiovascular diseases indicated that statins elicited provocative and unexpected benefits for reducing a number of different types of cancers, including colorectal carcinoma, melanoma, prostate and hepatocellular carcinoma, although in other cancer types the preclinical expectations of statins were dissapointing. In this review, we will describe the evidence and mechanisms underlying the potential beneficial use of statins and the role of protein prenylation in cancer prevention. Of relevance, the combination of statins with other anti cancer drugs may be a significant asset in malignancies resistant to current therapy.

Keywords: Cholesterol, Isoprenoids, Protein modification, Chemotherapy, Hedgehog pathway, proliferation, hepatocellular carcinoma, geranylgeranyl pyrophosphate, carboxyesterases, cell adhesion

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 19 April, 2012
Page: [303 - 315]
Pages: 13
DOI: 10.2174/187152012800228715
Price: $65

Article Metrics

PDF: 75